10-K/A: NanoVibronix Files Amended 10-K to Correct Auditor Consent

NanoVibronix has filed an amendment to its annual report to correct the location of its former auditor's consent and include updated certifications.

Summary

• NanoVibronix, Inc. filed an amendment to its annual report on Form 10-K for the fiscal year ended December 31, 2023.
• The amendment was made solely to correct the city and state of Marcum LLP, the company's former independent registered public accounting firm, in their consent.
• The original Form 10-K was filed on April 8, 2024.
• This amendment includes new certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002.
• No financial statements are included in this amendment, and it does not modify or update the original Form 10-K in any other way.
• The number of outstanding shares as of April 8, 2024, was 2,784,354.
• The aggregate market value of voting stock held by non-affiliates as of June 30, 2023, was approximately $4,830,581.

Sentiment

Score: 7

Explanation: The document is a routine amendment to correct a minor error, which is neither positive nor negative. The certifications from the CEO and CFO provide some reassurance.

Positives

• The company is taking steps to ensure compliance with SEC regulations by correcting the auditor's consent.
• The CEO and CFO have provided certifications confirming the accuracy of the report.

Risks

• The need to amend the original filing may indicate potential issues with internal controls or processes.
• The company's previous auditor, Marcum LLP, is no longer their independent registered public accounting firm.

Management Comments

• The Chief Executive Officer and Chief Financial Officer have certified that the report does not contain any untrue statements or omissions of material facts.

Industry Context

This filing is a standard regulatory requirement for publicly traded companies and the amendment is a routine correction.

Comparison to Industry Standards

• The filing of a Form 10-K/A to correct an auditor's consent is not uncommon and is a standard practice to ensure compliance with SEC regulations.
• Other companies such as 'Medtronic' and 'Boston Scientific' also file similar forms to ensure compliance with SEC regulations.
• The need for an amendment suggests a potential lapse in internal controls, which is a concern that other companies in the medical device industry also face.

Stakeholder Impact

• Shareholders are informed of the correction to the annual report.
• The company demonstrates its commitment to regulatory compliance.

Key Dates

Keywords

Form 10-K, Amendment, Auditor Consent, Sarbanes-Oxley Act, Financial Reporting, NanoVibronix, Compliance, SEC